Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve

This audio article is from VisualFieldTest.com.Read the full article here: https://visualfieldtest.com/en/can-glaucoma-damage-be-reversed-first-human-epigenetic-reprogramming-trial-targets-the-optic-nerveTest your visual field online: https://visualfieldtest.comSupport the show so new episodes keep coming: https://www.buzzsprout.com/2563091/supportExcerpt:Can Glaucoma Damage Be Reversed? First Human Epigenetic Reprogramming Trial Targets the Optic Nerve Updated August 11, 2026 Bottom line ER-100 is the first human clinical trial of a partial epigenetic reprogramming therapy, but it is not yet evidence that glaucoma damage can be reversed in people. Life Biosciences is testing ER-100 in a small, first-in-human Phase 1 study involving adults with open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The treatment delivers genetic instructions for three transcription factors—OCT4, SOX2, and KLF4, collectively called OSK—to retinal ganglion cells using an adeno-associated virus type 2 vector. Oral doxycycline is then used for eight weeks to activate the therapeutic genes. [ClinicalTrials.gov study record] () The scientific idea is fundamentally different from conventional glaucoma treatment. Instead of lowering intraocular pressure, ER-100 is intended to make damaged but living retinal ganglion cells behave more like younger, healthier cells. The preclinical evidence is unusually ambitious: studies in mice reported retinal ganglion cell survival, optic nerve axon growth, improved electrical retinal responses, and improved visual behavior. Company-presented nonhuman-primate data reported recovery of pattern electroretinogram responses and improved optic nerve axon survival after an experimental optic nerve stroke. However, the primate findings have been publicly described mainly through company disclosures and a 2023 Association for Research in Vision and Ophthalmology presentation rather than a detailed, independent, peer-reviewed clinical-efficacy publication. [Nature study] () [Life Biosciences primate disclosure] () As of August 11, 2026, no human vision benefit, epigenetic reset, retinal ganglion cell regeneration, or long-term safety result has been publicly reported. Life Biosciences has confirmed that the first participant was dosed, but the trial remains an early safety study with no results posted on ClinicalTrials.gov. [Life Biosciences first-dose announcement] () [ClinicalTrials.gov record] () The fairest conclusion is: > Glaucoma has not yet entered the era of proven optic-nerve restoration. It has entered the era of the first credible human experiment testing whether optic-nerve cells can be rejuvenated rather than merely protected. --- Why current glaucoma treatments do not reverse damage Glaucoma damages retinal ganglion cells, the nerve cells that collect visual information from the retina. Their long axons form the optic nerve and carry signals to the brain. Once retinal ganglion cells and their axons are permanently lost, current treatments cannot replace them. Standard treatments—including eye drops, laser treatment, and glaucoma surgery—primarily reduce intraocular pressure. Lowering pressure can slow or prevent additional optic nerve damage, but it does not normally restore lost visual field. [National Eye Institute] () [American Academy of Ophthalmology patient information] () This is why glaucoma care is generally described as preservation rather than restoration. Lowering pressure remains the only proven treatment strategy for controlling ordinary open-angle glaucoma, although disease progression can sometimes continue even when pressure is considered acceptable. [National Institute for Health and Care Excellence] () The difficulty is not only that retinal ganglion cells die. Their axons must also travel through the optic nerve and connect with appropriate visual centers in the brain. The National Eye Institute has emphasized that the failure of adult human retinal ganglion cells to regenerate and reconnect explains much of the irreversibility of optic-nerve-related vision loss. [National Eye Institute optic-nerve regeneration report] () ER-100 is designed to intervene at a different level: Conventional treatment: reduce the mechanical stress caused by intraocular pressure. ER-100: alter gene regulation inside retinal ganglion cells. Potential goal: preserve stressed cells, restore the function of injured cells, and possibly reactivate some regenerative capacity. ER-100 is therefore not a replacement for pressure control. Even if it works, a person with glaucoma would still be expected to need standard treatment to reduce the original disease stress. --- What ER-100 is ER-100 is described by Life Biosciences as AAV2-OSK: an adeno-associated virus type 2 vector carrying genetic instructions for OCT4, SOX2, and KLF4. The vector is administered by an intravitreal injection, meaning an injection into the gel-like vitreous cavity inside the eye. [Life Biosciences] () The vector is intended to deliver the OSK instructions mainly to retinal ganglion cells. It is not designed to edit the patient’s existing DNA sequence in the way a genome-editing system would. However, that does not mean it carries no genetic or biological risk: the vector can persist in cells, transgene expression may vary, and rare vector-genome integration is a general consideration in gene therapy. The treatment includes a separate control mechanism. According to the ClinicalTrials.gov record: The patient receives a single dose of ER-100. The viral vector remains in the eye. The patient takes oral doxycycline for 56 days. Doxycycline activates OSK expression through an inducible genetic switch. Doxycycline is stopped after eight weeks. The exact numeric vector doses for the dose-escalation groups have not been publicly listed in the main ClinicalTrials.gov record. The trial states that at least two dose levels will be assessed in the open-angle glaucoma cohort. [ClinicalTrials.gov] () What “epigenetic reprogramming” means The epigenome consists of chemical and structural controls that influence which genes are turned on or off. These controls include DNA methylation, chemical changes to histone proteins, and changes in how DNA is packaged. Epigenetic reprogramming does not necessarily change the underlying DNA letters. Instead, it attempts to alter the instructions that determine how the cell reads its existing genome. The theory behind ER-100 is that aging and injury gradually disturb the gene-regulation program that keeps retinal ganglion cells functional. According to this model, some of the damage may be a loss of youthful cellular information rather than irreversible destruction of every component of the cell. OSK is intended to push the cell toward a younger gene-expression state without converting it completely into a stem cell. --- How OCT4, SOX2, and KLF4 are supposed to rejuvenate retinal ganglion cells The three factors are transcription factors. They bind DNA and influence large networks of other genes. OCT4 OCT4 is a major regulator of cell identity and cellular reprogramming. In the original induced-pluripotent-stem-cell experiments, OCT4 helped activate a developmental program that could return adult cells to a stem-cell-like state. In ER-100, the aim is not to drive retinal ganglion cells all the way back to pluripotency. Instead, OCT4 is intended to help reopen or reorganize portions of the gene-regulatory landscape associated with cellular repair and youthfulness. SOX2 SOX2 is another key reprogramming factor. It helps alter chromatin accessibility—the degree to which DNA can be reached by gene-regulating proteins. In retinal ganglion cells, this may help reactivate genes involved in neuronal maintenance, axon growth, stress resistance, and synaptic function. The exact human retinal ganglion cell targets of ER-100 remain unproven. KLF4 KLF4 is involved in cell identity, chromatin regulation, stress responses, and reprogramming. It works together with OCT4 and SOX2 to alter gene-expression networks. The intended result is not simply a lower “epigenetic age” on a laboratory test. The therapeutic claim is that the cells should function better: maintaining axonal transport, resisting injury, and potentially regaining some ability to extend or repair axons. The proposed sequence of events The proposed mechanism can be summarized as: Age or injury alters gene regulation in retinal ganglion cells. These cells become less able to maintain axons and respond to stress. OSK temporarily changes transcription and chromatin organization. DNA methylation patterns and gene expression move toward a more youthful state. The retinal ganglion cells become more resilient or regain some regenerative capacity. Visual signaling improves if enough cells and axons remain connected. The mouse work supports several steps in this chain, but the complete sequence has not been demonstrated in humans. The original Nature study reported that OSK restored youthful DNA methylation patterns and gene-expression profiles in mouse retinal ganglion cells, and that the effect required the DNA-demethylation machinery involving TET1, TET2, and TDG. This is stronger evidence than merely showing that a methylation clock changed, but it still does not prove that aging in human glaucoma is primarily caused by epigenetic information loss. [Nature study] () --- Why ER-100 uses three factors rather than all four Yamanaka factors The original four-factor reprogramming combination is: OCT4 SOX2 KLF4 c-MYC The four-factor combinatioSupport the show